Gilead-backed Kite, a global biopharmaceutical company, completed the acquisition of Tmunity Therapeutics, a clinical-stage, private biotech company. Financial terms were not disclosed. “Kite has demonstrated an ability to globally scale cell therapy and address the unique challenges and opportunities that cell therapy represents, which are quite different in material ways than traditional pharmaceutical or biotech approaches. Kite’s singular focus on cell therapy makes them unique and particularly nimble,” Carl June, Tmunity Founder.